Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 2Phase 2 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Other solid neoplasm 1Lymphoid 1

Conditions

Solid Cancers 1Neoplasms 1Lymphoma, Non-Hodgkin 1Advanced Solid Tumors 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × emactuzumab × Clear all
NCT02323191 2020-08-27

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
221 enrolled

Solid Cancers

NCT02760797 2018-05-22

A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
38 enrolled
Tumor-Agnostic

Neoplasms

NCT03369964 2018-04-05

A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Hoffmann-La Roche

Phase 1 Withdrawn
Lymphoid

Lymphoma, Non-Hodgkin

NCT01494688 2018-03-16

A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
217 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡